CalciMedica, Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>CalciMedica, Inc. has filed its Q1 2024 10-Q report, detailing financial activities and corporate transactions.</b>

AI Summary

CalciMedica, Inc. (CALC) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. CalciMedica, Inc. filed a 10-Q report for the period ending March 31, 2024. The company's fiscal year ends on December 31. The filing includes data related to various financial instruments and transactions, including warrants, promissory notes, and stock options. Specific dates mentioned include March 31, 2024, and January 19, 2024, related to private placements and warrant issuances. The report references prior company names, including Graybug Vision, Inc., indicating a history of corporate changes.

Why It Matters

For investors and stakeholders tracking CalciMedica, Inc., this filing contains several important signals. This filing provides a snapshot of CalciMedica's financial position and activities during the first quarter of 2024, which is crucial for investors to assess the company's performance and potential. The inclusion of details on warrants, private placements, and prior corporate names suggests ongoing financial restructuring and strategic initiatives that could impact future valuation.

Risk Assessment

Risk Level: medium — CalciMedica, Inc. shows moderate risk based on this filing. The filing is a standard 10-Q, which provides a routine update on financial performance and does not contain significant new information that would drastically alter the risk profile, but it does indicate ongoing financial activities like warrant issuances.

Analyst Insight

Investors should review the detailed financial statements and disclosures within the 10-Q to understand the company's current financial health and the implications of its various financial instruments.

Key Numbers

• 2024-03-31 — Period End Date (10-Q filing)
• 2024-05-13 — Filing Date (10-Q filing)
• 2023-03-22 — Date of Name Change (From Graybug Vision, Inc. to CalciMedica, Inc.)

Key Players & Entities

• CalciMedica, Inc. (company) — Filer of the 10-Q report
• Graybug Vision, Inc. (company) — Former company name
• 2024-03-31 (date) — Period of report for the 10-Q
• 2024-05-13 (date) — Filing date of the 10-Q
• 2024-01-19 (date) — Date related to private placement and warrants

FAQ

Risk Factors

• Financial Instruments and Fair Value Measurements [medium — financial]: The company's financial statements include recurring fair value measurements for various instruments, including warrants and money market funds, with Level 3 inputs indicating significant unobservable data.

Key Dates

• 2024-03-31: Quarterly Period End — Reporting period for the 10-Q
• 2024-05-13: Filing Date — Date the 10-Q was officially submitted

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC). (Provides a regular update on the company's financial performance and condition.)

Warrants

Financial instruments that give the holder the right, but not the obligation, to purchase a company's stock at a specific price. (Indicates potential future dilution and financial obligations for the company.)

Private Placement

The sale of securities to a select group of investors, rather than through a public offering. (Often used for raising capital quickly, but can involve complex terms and potentially less favorable pricing.)

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share CALC The Nasdaq Capital M

Filing Documents

• calc-20240331.htm (10-Q) — 2051KB
• calc-ex31_1.htm (EX-31.1) — 14KB
• calc-ex31_2.htm (EX-31.2) — 14KB
• calc-ex32_1.htm (EX-32.1) — 9KB
• calc-ex32_2.htm (EX-32.2) — 9KB
• 0000950170-24-058744.txt (&nbsp;) — 7601KB
• calc-20240331.xsd (EX-101.SCH) — 1227KB
• calc-20240331_htm.xml (XML) — 1040KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 2 Condensed Consolidated Balance Sheets 2 Condensed Consolidated Statements of Operations 3 Condensed Consolidated Statement of Comprehensive Income (Loss) 4 Condensed Consolidated Statements of Stockholders' Equity (Deficit) 5 Condensed Consolidated Statements of Cash Flows 7 Notes to the Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 31 Item 4.

Controls and Procedures

Controls and Procedures 31

—OTHER INFORMATION

PART II—OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 32 Item 1A.

Risk Factors

Risk Factors 33 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 76 Item 3. Defaults Upon Senior Securities 76 Item 4. Mine Safety Disclosures 76 Item 5. Other Information 76 Item 6. Exhibits 77

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. CALCIMEDICA, INC. Condensed Consolidated Balance Sheets (in thousands, except par value and share amounts) (Unaudited) March 31, 2024 December 31, 2023 Assets Current assets Cash and cash equivalents $ 6,755 $ 5,530 Short-term investments 18,955 5,708 Prepaid expenses and other current assets 894 367 Total current assets 26,604 11,605 Property and equipment, net 153 167 Other assets 377 413 Total assets $ 27,134 $ 12,185 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 1,535 $ 1,419 Accrued clinical trial costs 1,000 1,141 Accrued other 1,752 1,468 Total current liabilities 4,287 4,028 Long-term liabilities Warrant liability 5,600 — Total liabilities 9,887 4,028 Commitments and contingencies (Note 9) Stockholders' equity Preferred stock, $ 0.0001 par value; 10,000,000 shares and no shares authorized at March 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively — — Common stock, $ 0.0001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 10,740,115 and 5,754,505 issued and outstanding at March 31, 2024 and December 31, 2023, respectively 3 1 Additional paid-in capital 163,195 154,218 Accumulated deficit ( 145,934 ) ( 146,064 ) Accumulated other comprehensive income (loss) ( 17 ) 2 Total stockholders' equity 17,247 8,157 Total liabilities and stockholders' equity $ 27,134 $ 12,185 See accompanying notes to unaudited condensed consolidated financial statements. 2 CALCIMEDICA, INC. Condensed Consolidated Statemen ts of Operations (in thousands, except share and per share amounts) (Unaudited) Three Months Ended March 31, 2024 2023 Operating expenses: Research and development $ 2,944 $ 6,491 General and adminis

View Full Filing

View this 10-Q filing on SEC EDGAR